Preclinical-stage pharmaceutical company

New molecules from the team that brought cannabinoid medicine to approval.

Phytanix Bio designs new chemical entities around cannabinoid, cannabinoid-like and Kv7 potassium-channel targets in epilepsy, depression, obesity and liver disease. Every program is a new molecule with its own composition-of-matter patents. None is a botanical extract or a reformulation.

4 programsCNS · metabolic · liver

Granted patentson 3 of 4 programs

Phase 1 targetH2 2027

Each program is a new small molecule with its own composition-of-matter patents. Schematic only.

Science

Drug-like molecules aimed at validated targets

We aim to build a pipeline of de-risked drug candidates. We start with mechanisms that preclinical or clinical data have already proven out. Then we use medicinal chemistry to fix what held earlier molecules back: dose, oral form, tissue exposure or side-effect profile.

New chemical entities

Each candidate is a new molecule protected by its own composition-of-matter patents. That gives a full patent life and a clear regulatory identity, which botanical cannabinoids do not have.

Validated biology

Kv7.2/7.3 activation, CB1 modulation and CBD-like anticonvulsant activity have all been tested in humans. That leaves less mechanism risk and puts the work on the molecule.

Development know-how

Our team was closely involved in taking Sativex^® and Epidiolex^® through development, IP strategy and global approval. We apply that DMPK, regulatory and patent experience from the first experiment.

How we work

A lean team, with AI in the workflow

We are building AI tools into how a small, experienced team works. We use them to move faster and spend less. Experimental data still decides what advances.

Now: reviewing the scientific, patent and competitive literature, and preparing development and regulatory documents.
Next: using these tools to support the design, synthesis and testing of appropriate analogues.

Pipeline

Four programs across CNS, metabolic and liver disease

All four programs are preclinical. We plan to complete IND-enabling studies and begin Phase 1 in the second half of 2027.

Program	Mechanism	Lead indications
PHYX001	Kv7.2/7.3 activator	Focal seizures, depression, KCNQ2-DEE
PHYX002	CBD analogue	CNS disorders
PHYX003	Multi-modal CB1 modulator	Obesity and metabolic disease
PHYX004	Cannabinoid–stilbenoid hybrid	MASLD / MASH, seizure disorders

No Phytanix program has been tested in humans. Preclinical results are preliminary and do not predict clinical outcomes.

PHYX001

Next-generation Kv7.2/7.3 activator

CNS · epilepsy · mood

PHYX001 acts on the Kv7.2/7.3 potassium channel, a target that another sponsor validated in Phase 3 focal-epilepsy trials before filing its NDA in September 2026. The program covers two chemical scaffolds and opens a route to parenteral formulations, a use the oral leaders in this class do not address.

Potential indications: Focal seizures, major depressive disorder, bipolar depression, KCNQ2 developmental epileptic encephalopathy, tinnitus.
Partnering: We are open to licensing or co-development, including for parenteral and acute-care uses. Preclinical data and IP details are available under a mutual non-disclosure agreement.

PHYX002

CBD analogue for a solid oral dosage form

CNS · epilepsy

Cannabidiol is an approved anticonvulsant, but it is dosed at 10–25 mg/kg/day as an oil-based oral solution and has no composition-of-matter protection. PHYX002 is a proprietary analogue designed to keep CBD's pharmacology, but at a much lower dose. The goal is a tablet or capsule.

Preclinical findings: Efficacy equivalent to CBD at a fraction of the dose in preclinical models. Data on file; to be tested clinically.
Development rationale: A lower dose and a solid oral dosage form could make treatment easier for patients and carers. A new molecule also brings a full 20-year patent term.

PHYX003

Multi-modal cannabinoid for metabolic disease

Metabolic · obesity

Blocking CB1 receptors reduced weight in patients, but rimonabant was withdrawn in 2008 because of psychiatric side effects. Most current efforts try to keep similar molecules out of the brain. PHYX003 takes a different approach: it is not an orthosteric CB1 inverse agonist. It acts through several mechanisms, and is designed so that it does not depend on peripheral restriction to avoid the negative neuropsychiatric effects at CB1 receptors.

~7.5%weight loss, monotherapy

22.5%with low-dose tirzepatide

Study: Diet-induced obese mouse model. Preclinical; data on file.
Positioning: An oral add-on to GLP-1 therapies and other metabolic drugs. Its efficacy, safety and neuropsychiatric profile have to be confirmed in clinical trials.

PHYX004

Cannabinoid–stilbenoid hybrids

Liver · metabolic · CNS

A family of hybrid molecules that combines cannabinoid and stilbenoid chemistry. Invented at our UK subsidiary, these compounds behaved like CBD in in vivo seizure models. Early work also points to possible PPAR activity, which supports development as an add-on therapy in metabolic dysfunction-associated steatotic liver disease (MASLD).

Intellectual property: Granted in the US, UK, China, Japan, Canada and South Korea, with further applications pending. Includes a new chemical entity and a first-medical-use claim.
Next step: Selecting a lead candidate from a set of next-generation analogues.

Heritage

We have done this before

The core team helped build GW Pharmaceuticals. GW took the first regulatory-approved cannabis-based medicine to market and was acquired by Jazz Pharmaceuticals.

2010

Sativex^®

Approved in the UK and Spain in 2010 for MS spasticity, the first regulatory-approved cannabis-based medicine.

2018

Epidiolex^®

FDA approval in Dravet and Lennox-Gastaut syndromes. Net sales passed $1 billion in 2025.

2021

Jazz acquires GW

A $7.2 billion acquisition that set the value benchmark for cannabinoid therapeutics.

Today

Phytanix Bio

The same development, patent and DMPK experience, now applied to new chemical entities.

Leadership

A small team with deep cannabinoid development experience

We expect to add scientific advisors after the current financing round.

Barrett Evans

CEO & Co-Founder

Leads corporate strategy, financing and the listing process. Managing Director of EMC2 Capital.

Colin Stott

COO & Co-Founder

Former R&D Operations and Scientific Affairs Director (International) at GW Pharmaceuticals. Over 25 years in cannabinoid development, including Sativex^® and Epidiolex^®.

Dominic Schiller

Chief IP Officer & Co-Founder

The patent attorney behind GW Pharmaceuticals' cannabinoid IP portfolio and patent strategy.

Guy Webber

Pre-Clinical Development Director

Former ADME/DMPK specialist at GW Pharmaceuticals, with experience taking cannabinoid DMPK through IND-enabling studies.

Investors

Private, and preparing for public markets

Phytanix Bio is a privately held Nevada corporation with operating subsidiaries in the United Kingdom. We are evaluating a public listing, including through a strategic combination with a listed company, to fund the pipeline through Phase 1.

H2 2026

Listing and financing

Complete a listing transaction and close a financing round.

H2 2027

Into the clinic

Complete IND-enabling studies and begin Phase 1.

2028+

Clinical data

Phase 1 readouts and partnering, starting with the Kv7 program.

This website does not offer to sell, or solicit an offer to buy, any security. Detailed preclinical data are available to qualified parties under a mutual non-disclosure agreement.

Contact

Talk to us

Contact us about investment, licensing or scientific collaboration. We can share our full presentation and data on file under NDA.

Barrett EvansChief Executive Officer · investors, corporate development and licensing

bevans@phytanix.com

Colin StottChief Operating Officer · R&D and scientific partnerships

cs@phytanix.com